---
title: "VYNE: YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292680359.md"
description: "YB-101, a first-in-class anti-TSHR antibody, is advancing through clinical trials to address significant unmet needs in Graves' Disease and thyroid eye disease. Backed by $200M in funding and a strong leadership team, the company targets a $2B+ US market with a differentiated, convenient therapy.Original document: VYNE Therapeutics Inc. [VYNE] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-14T22:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292680359.md)
  - [en](https://longbridge.com/en/news/292680359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292680359.md)
generator: "portal-rs"
---

# VYNE: YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach

YB-101, a first-in-class anti-TSHR antibody, is advancing through clinical trials to address significant unmet needs in Graves' Disease and thyroid eye disease. Backed by $200M in funding and a strong leadership team, the company targets a $2B+ US market with a differentiated, convenient therapy.

Original document: VYNE Therapeutics Inc. \[VYNE\] Slides Release — Jul. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VYNE.US](https://longbridge.com/en/quote/VYNE.US.md)
- [YARW.US](https://longbridge.com/en/quote/YARW.US.md)

## Related News & Research

- [Yarrow Bioscience files amended 8-K report on merger exchange ratio update](https://longbridge.com/en/news/295840217.md)
- [Walmart store workers have a new responsibility: correcting AI errors](https://longbridge.com/en/news/296213777.md)
- [iQIYI: Sequential revenue growth and AI-driven content expansion fueled profitability and global reach](https://longbridge.com/en/news/296235524.md)
- [Indra says FaRADAI R&D validates explainable AI to assess threats, plot safe routes in military operations](https://longbridge.com/en/news/296213236.md)
- [ZAPLOX: Q2 2026 saw a return to profitability and strong cost control, setting the stage for future growth](https://longbridge.com/en/news/296186495.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**